Trastuzumab combined with chemotherapy has been established as the standard first-line treatment for HER2-positive advanced GC [105], but due to primary or acquired resistance to trastuzumab, only a subset of patients benefit from this treatment. This evidence concerns the gene ERBB2 and gastric cancer.